Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Astellas Pharma Europe B.V. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary aim is to show whether a reduction in tumor related mRNAs and a panel of selected miRNAS can be used to personalize enzalutamide therapy.
Furthermore the aim is to explore the relation between drug exposure and the decrease in the selected biomarkers and treatment response.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Enzalutamide, 160mg, 40 mg soft capsules, once daily | Drug | Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label |
| Measure | Description | Time Frame |
|---|---|---|
| Relation between biomarker response and therapeutic response | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Relation between drug exposure, biomarker and therapeutic response | 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
chemotherapy naive patients with metastatic CRPC
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nielka van Erp, PharmD, PhD | Radboud University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Jeroen Bosch Ziekenhuis | 's-Hertogenbosch | Netherlands | ||||
| Radboud UMC |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32408351 | Result | Benoist GE, van Oort IM, Boerrigter E, Verhaegh GW, van Hooij O, Groen L, Smit F, de Mol P, Hamberg P, Dezentje VO, Mehra N, Gerritsen W, Somford DM, van Erp NPH, Schalken JA. Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. Clin Chem. 2020 Jun 1;66(6):842-851. doi: 10.1093/clinchem/hvaa095. |
| Label | URL |
|---|---|
| paper | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
blood
| Nijmegen |
| 6500HB |
| Netherlands |
| Canisius Wilhelmina Ziekenhuis | Nijmegen | Netherlands |
| ID | Term |
|---|---|
| C540278 | enzalutamide |
Not provided
Not provided
Not provided